PurcisionTM Technology

Enabled by the proprietary Purcision technology, LSAMs of pure drug are suspended at time of use and delivered directly to the disease site where the particles are retained as a depot continuously releasing drug molecules as the particles dissolve over time.

Large Surface Area Microparticles (LSAMs)

  • Intratumoral

  • Peritumoral

  • Intraperitoneal

  • Resection bed

  • Intravesicular

  • Instillation

  • Inhalation

  • Intracystic

  • Topical

Advantages

High sustained local concentration

Continuous tumor kill

Immunogenic effect

Gradual subtoxic clearance

Composition of matter patent on LSAMs protects particle regulatory specifications:

Size

Surface Area

Density

Dissolution

LSAMs are Superior to IV Drugs for Intratumoral Delivery

Taxane Solution for Injection Tumor Site

Paclitaxel or docetaxel injections are designed for IV administration and rapidly diffuse out of the tumor if injected intratumorally.

LSAM-PTX and LSAM-DTX are designed for local administration and become entrapped in the tumor allowing for high, continuous, local therapeutic drug release over time

Tumor tissue concentration of LSAM-PTX and LSAM-DTX versus comparators all given intratumorally in a mouse model

Proprietary Purcision Platform
Large Surface Area Microparticle LSAM Production

API Crystals

  • Large and bulky crystals
  • Infeasible to form pharmaceutically acceptable particle suspension
  • Limited to dissolution in solvent as a solution for IV delivery
  • GMP full scale production suitable for clinical supplies and commercial launch
  • Uniquely uses supercritical fluid carbon dioxide as antisolvent to precipitate LSAMs
  • Platform technology for multiple drug classes including taxanes, platins, TKIs, PARPIs, others

LSAMs

  • 100% pure drug with no excipients or coting agents
  • Right particle size for tumor retention
  • Increased surface area for high, continuous, local therapeutic drug release
  • Decreased bulk density for excellent suspension uniformity
 

References:  NanOlogy internal data, 2015-2022.